Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04209205
Other study ID # CAIN457P12302
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date January 29, 2020
Est. completion date May 17, 2022

Study information

Verified date August 2023
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to provide up to 52 weeks of efficacy, safety and tolerability data to support registration of intravenous (i.v.) secukinumab (Initial dose of 6 mg/kg at Baseline (BSL) followed thereafter with 3 mg/kg administered every four weeks) in patients with active psoriatic arthritis (PsA) despite current or previous Non-steroidal anti-inflammatory drugs (NSAIDs), Disease-modifying antirheumatic drugs (DMARDs) and/or anti-tumor necrosis factor (TNF) therapy.


Description:

This multicenter study used a randomized, double-blind, placebo-controlled, parallel-group design. A screening (SCR) period running up to 10 weeks before randomization was used to assess subject eligibility followed by a treatment period of 52 weeks. At baseline, 381 patients with active psoriatic arthritis were randomized to one of the two treatment groups in a 1:1 randomization: Group 1: Approximately 190 patients with active psoriatic arthritis; These patients received secukinumab 6 mg/kg i.v. at BSL, followed by the administration of secukinumab 3 mg/kg i.v. every four weeks starting at Week 4. Group 2: Approximately 190 patients with active psoriatic arthritis; These patients received i.v. placebo at BSL and at Weeks 4, 8, and 12, followed by the administration of secukinumab 3 mg/kg i.v. every four weeks starting at Week 16. Study consisted of 4 periods: a screening period (up to 10 weeks), treatment period 1 (total duration of 16 weeks) and treatment period 2 (total duration of 36 weeks) followed by a safety follow up period of 8 weeks after the end of treatment visit (i.e., Week 52). Primary endpoint analysis will be performed with Week 16 data (last patient completing Treatment period 1 (Week 16). Long-term efficacy and safety assessments will be performed up to Week 52.


Recruitment information / eligibility

Status Completed
Enrollment 381
Est. completion date May 17, 2022
Est. primary completion date May 17, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Patients eligible for inclusion in this study had to fulfill all of the following criteria: - Diagnosis of PsA classified by CASPAR criteria and with symptoms for at least 6 months with moderate to severe PsA who must have at Baseline =3 tender joints out of 78 and =3 swollen out of 76 (dactylitis of a digit counts as one joint each) - Rheumatoid factor and anti-CCP antibodies negative at screening - Diagnosis of active plaque psoriasis or nail changes consistent with psoriasis or documented history of plaque psoriasis - Subjects with PsA should have taken NSAIDs for at least 4 weeks prior to randomization with inadequate control of symptoms or at least one dose if stopped due to intolerance to NSAIDs - Subjects taking corticosteroids must be on a stable dose of =10 mg/day prednisone or equivalent for at least 2 weeks before randomization and should remain on a stable dose up to Week 16 - Subjects taking MTX (= 25 mg/week) are allowed to continue their medication if the dose is stable for at least 4 weeks before randomization and should remain on a stable dose up to Week 52. Patients fulfilling any of the following criteria are not eligible for inclusion in this study: - Chest X-ray or chest MRI with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician - Subjects taking high potency opioid analgesics (e.g. methadone, hydromorphone, morphine) - Previous exposure to secukinumab or other biologic drug directly targeting IL-17 or IL-17 receptor - Ongoing use of prohibited psoriasis treatments / medications (e.g., topical corticosteroids, UV therapy) at randomization. The following wash-out periods need to be observed: - Oral or topical retinoids- 4 weeks - Photochemotherapy (e.g. PUVA)- 4 weeks - Phototherapy (UVA or UVB)- 2 weeks - Topical skin treatments (except in face, eyes, scalp and genital area during screening, only corticosteroids with mild to moderate potency)- 2 weeks - Any intramuscular or intravenous corticosteroid treatment within 4 weeks before randomization. - Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before randomization. - Subjects who have previously been treated with more than 3 different TNF inhibitors (investigational or approved). - Subjects who have ever received biologic immunomodulating agents, investigational or approved except for those targeting TNFa. - Previous treatment with any cell-depleting therapies including but not limited to anti-CD20 or investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AIN457 6 mg/kg i.v.
AIN457 6 mg/kg delivered by i.v. infusion
Placebo
Matching placebo to AIN457 i.v. infusion
AIN457 3 mg/kg
AIN457 3 mg/kg delivered by i.v. infusion

Locations

Country Name City State
Brazil Novartis Investigative Site Salvador BA
Brazil Novartis Investigative Site Sao Paulo SP
Bulgaria Novartis Investigative Site Burgas
Bulgaria Novartis Investigative Site Plovdiv
Bulgaria Novartis Investigative Site Plovdiv
Bulgaria Novartis Investigative Site Sofia
Bulgaria Novartis Investigative Site Sofia
Colombia Novartis Investigative Site Barranquilla Atlantico
Colombia Novartis Investigative Site Bogota
Colombia Novartis Investigative Site Bucaramanga Santander
Colombia Novartis Investigative Site Cundinamarca
Czechia Novartis Investigative Site Prague 2
Czechia Novartis Investigative Site Praha 4
Czechia Novartis Investigative Site Praha 5
Czechia Novartis Investigative Site Uherske Hradiste
Greece Novartis Investigative Site Athens
Greece Novartis Investigative Site Thessaloniki
Guatemala Novartis Investigative Site Guatemala
Guatemala Novartis Investigative Site Guatemala
Guatemala Novartis Investigative Site Guatemala City
India Novartis Investigative Site Bangalore Karnataka
India Novartis Investigative Site Nashik Maharashtra
India Novartis Investigative Site New Delhi
India Novartis Investigative Site Surat Gujarat
Malaysia Novartis Investigative Site Kuching Sarawak
Malaysia Novartis Investigative Site Selangor Darul Ehsan
Malaysia Novartis Investigative Site Seremban Negeri Sembilan
Philippines Novartis Investigative Site Dasmarinas Cavite
Philippines Novartis Investigative Site Lipa City Batangas
Philippines Novartis Investigative Site Manila
Philippines Novartis Investigative Site Quezon City
Poland Novartis Investigative Site Karwiany
Poland Novartis Investigative Site Krakow
Poland Novartis Investigative Site Krakow Malopolskie
Poland Novartis Investigative Site Sochaczew
Poland Novartis Investigative Site Warszawa
Russian Federation Novartis Investigative Site Kemerovo
Russian Federation Novartis Investigative Site Nizhny Novgorod
Russian Federation Novartis Investigative Site Rostov On Don
Russian Federation Novartis Investigative Site Saint Petersburg
Russian Federation Novartis Investigative Site St Petersburg
Russian Federation Novartis Investigative Site Yaroslavl
Russian Federation Novartis Investigative Site Yekaterinburg
South Africa Novartis Investigative Site Panorama Western Cape
South Africa Novartis Investigative Site Stellenbosch
Thailand Novartis Investigative Site Bangkok
Thailand Novartis Investigative Site Bangkoknoi Bangkok
Thailand Novartis Investigative Site Khon Kaen THA
Thailand Novartis Investigative Site Songkhla Hat Yai
Turkey Novartis Investigative Site Bursa Gorukle
United States Novartis Investigative Site Austin Texas
United States Novartis Investigative Site Birmingham Alabama
United States Novartis Investigative Site Bowling Green Kentucky
United States Novartis Investigative Site Clearwater Florida
United States Novartis Investigative Site Denver Colorado
United States Novartis Investigative Site Duncansville Pennsylvania
United States Novartis Investigative Site Fountain Valley California
United States Novartis Investigative Site Fullerton California
United States Novartis Investigative Site Greensboro North Carolina
United States Novartis Investigative Site Indianapolis Indiana
United States Novartis Investigative Site Jackson Tennessee
United States Novartis Investigative Site La Mesa California
United States Novartis Investigative Site Lincoln Nebraska
United States Novartis Investigative Site Marietta Georgia
United States Novartis Investigative Site Mesquite Texas
United States Novartis Investigative Site Miami Florida
United States Novartis Investigative Site Middleburg Heights Ohio
United States Novartis Investigative Site Newport News Virginia
United States Novartis Investigative Site Ocoee Florida
United States Novartis Investigative Site Oklahoma City Oklahoma
United States Novartis Investigative Site Plantation Florida
United States Novartis Investigative Site Rochester New York
United States Novartis Investigative Site Saint Louis Missouri
United States Novartis Investigative Site Santa Monica California
United States Novartis Investigative Site Tampa Florida
United States Novartis Investigative Site Tulsa Oklahoma
United States Novartis Investigative Site Upland California
United States Novartis Investigative Site Van Nuys California
United States Novartis Investigative Site Voorhees New Jersey
United States Novartis Investigative Site West Hills California
United States Novartis Investigative Site Winter Park Florida

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Brazil,  Bulgaria,  Colombia,  Czechia,  Greece,  Guatemala,  India,  Malaysia,  Philippines,  Poland,  Russian Federation,  South Africa,  Thailand,  Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With American College of Rheumatology 50 (ACR50) Response Comparison Between Treatment Groups Using Non-responder Imputation at Week 16 (Full Analysis Set) Percentage of participants with active psoriatic arthritis (PsA) who achieved an American College of Rheumatology 50 (ACR50) response
The ACR50 is a composite measure defined as both improvement of 50% in the number of tender and number of swollen joints, and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP)
Baseline up to Week 16
Secondary Percentage of Participants With American College of Rheumatology 20 (ACR20) Response Comparison Between Treatment Groups Using On-responder Imputation at Week 16 (Full Analysis Set) Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • = 20% improvement in 78 tender joint count; • = 20% improvement in 76 swollen joint count; and • = 20% improvement in at least 3 of the 5 following parameters: ? Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]); ? Patient's global assessment of disease activity (measured on a 100 mm VAS); ? Physician's global assessment of disease activity (measured on a 100 mm VAS); ? Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ? C-Reactive Protein. Baseline up to Week 16
Secondary Percentage of Participants With Minimal Disease Activity (MDA 5/7) Comparison Between Treatment Groups Using On-responder Imputation at Week 16 (Full Analysis Set) MDA is assessed as 5 of the 7 following: = 1 tender and swollen joint; entheseal count, PASI = 1 or BSA =3%, PsA = 15 and disease activity = 20 (VAS) and HAQ-DI© = 0.5 Baseline up to Week 16
Secondary Percentage of Participants With Psoriasis Area and Severity Index 90 (PASi90) Score for Patients With a >= 3% Body Surface Area Psoriasis at Baseline Using On-responder Imputation at Week 16 (Full Analysis Set) Change from baseline of a 90% reduction in the PASI score for patients with a >= 3% body surface area psoriasis at baseline. Four body surface areas are evaluated (head, trunk and upper and lower limbs) for plaque, erythema, scaling and thickness. The degree of severity of each sign in each of the 4 body areas was assigned a score of 0 to 4. Scores ranged from 0 to 72 and higher scores represent worsening severity. Baseline up to Week 16
Secondary Psoriatic Arthritis Disease Activity Score (PASDAS) Change From Baseline Using Mixed Model Repeated Measures (MMRM) at Week 16 (Full Analysis Set) PASDAS is a composite measure developed to assess disease activity in Psoriatic arthritis. It is calculated by utilizing seven measures: Patient reported measures (excluding mental component) (SF-36-PCS), skin, peripheral joint counts (tender and swollen joint counts), dactylitis (LDI), enthesitis (LEI), acute phase response (CRP), and patient and physician global VAS scores. The typical score range is between 0 and 10. Smaller values on PASDAS indicate a better condition; a negative change from baseline indicates improvement. Baseline up to Week 16
Secondary Health Assessment Questionnaire - Disability Index (HAQ-DI) Score Change From Baseline Using Mixed Model Repeated Measures (MMRM) at Week 16 (Full Analysis Set) The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability. Baseline up to Week 16
Secondary Short Form 36-Physical Component Summary (SF36-PCS) Score Change From Baseline Using Mixed Model Repeated Measures (MMRM) at Week 16 (Full Analysis Set) The SF-36 is used to measure health-related quality of life with acute and chronic conditions. It consists of eight subscales that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Range of scoring is 0 -100, with higher scores indicating better health status. Baseline up to Week 16
Secondary Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score Change From Baseline Using Mixed Model Repeated Measures (MMRM) at Week 16 (Full Analysis Set) The FACIT-Fatigue is a 13 item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Response scale ranges from 0-4 and the total score range is 0 - 52. Higher scores indicate better quality of life Baseline up to Week 16
Secondary Modified Nail Psoriasis Severity Index (mNAPSI) Score Change From Baseline Using Mixed Model Repeated Measures (MMRM) at Week 16 (Full Analysis Set) The mNAPSI is an instrument to assess psoriatic nail involvement. Three groups of features (onycholysis and oil-drop dyshromia, pitting and crumbling) were graded on a scale from 0 to 3 for a total subscale of 0 to 9. The next 4 abnormalities (leukonychia, splinter hemorrhages, hyperkeratosis and red spots in the lunula) were graded as absent (0) or present (1) for a total subscale of 0 to 4. The total score was from 0-13 where higher scores represent worse nail disease. Baseline up to Week 16
Secondary Percentage of Participants With Complete Resolution of Dactylitis at Week 16 Using Non-responder Imputation (Dactylitis Subset) Dactylitis is characterized by swelling of the entire finger or toe. The Leeds Dactylitis Index (LDI) measures the ratio of the circumference of the affected (swollen) digit. The ratio of circumference is multiplied by a tenderness score, using a modification of LDI that is a binary score (1 for tender, 0 for non-tender). The LDI requires a finger circumference gauge or a dactylometer to measure digital circumference. Scores range from 0 - 20 and lower score indicates better outcome. Baseline up to Week 16
Secondary Percentage of Participants With Complete Resolution of Enthesitis at Week 16 Using Non-responder Imputation (Enthesitis Subset (LEI)) Enthesitis is inflammation of the enthesis which is where a a tendon or ligament attaches to the bone. The Leeds enthesitis index (LEI) is a validated index that uses 6 sites for evaluation of enthesitis: lateral epicondyle humerus L + R, proximal achilles L + R and medial condyle femur L+R. If enthesitis is present at any of the 6 sites, the subject is counted as a subject with enthesitis. Baseline up to Week 16
See also
  Status Clinical Trial Phase
Completed NCT04152759 - Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects Phase 1
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT01925768 - Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis Phase 3
Completed NCT01892436 - Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis Phase 3
Completed NCT01212770 - PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Phase 3
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT01212757 - PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Phase 3
Completed NCT03953378 - CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis
Recruiting NCT02572700 - Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis
Completed NCT02556034 - Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT02188654 - Metformin in Psoriatic Arthritis N/A
Completed NCT02164214 - Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)? Phase 3
Completed NCT01392326 - Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) Phase 3
Completed NCT01083693 - Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs N/A
Not yet recruiting NCT00517101 - Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy N/A
Completed NCT00133315 - TNFalfa Blocking Treatment of Spondylarthropathies Phase 4
Completed NCT00659412 - A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis Phase 2
Completed NCT00946686 - To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions Phase 1
Not yet recruiting NCT06059430 - Cohort Project of Patients With Inflammatory Rheumatism